EHJ - Cardiovascular Pharmacotherapy
Focusing on clinical cardiovascular pharmacology
Showing 24 of 849 results
ESC Journals
ESC Journals
ESC Journals
SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions
11 April 2026
ESC Journals
Response to SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions
11 April 2026
ESC Journals
Implementing sodium–glucose co-transporter 2 inhibitors in cardiovascular–kidney–metabolic syndrome: a multidisciplinary expert perspective
10 April 2026
ESC Journals
ESC Journals
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes Insights from SHEBAHEART big data registry
30 March 2026
ESC Journals
ESC Journals
Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions
19 March 2026
ESC Journals
Targeted anticoagulant reversal, unintended consequences: lessons from andexanet alfa
13 March 2026
ESC Journals
ESC Journals
A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy
27 February 2026
ESC Journals
Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study
17 February 2026
ESC Journals
A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF
16 February 2026
ESC Journals
Correction to: Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee
4 February 2026
ESC Journals
ESC Journals
Different aspects of myocardial intervention and pharmacological treatment
2 February 2026
ESC Journals
Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management
2 February 2026
ESC Journals
Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy
30 January 2026
ESC Journals
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention
29 January 2026
ESC Journals
Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial
22 January 2026
ESC Journals
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system
22 January 2026
ESC Journals
Withdrawing heart failure therapy after AF rhythm control: promise, caution, and perspective
20 January 2026
ESC Journals
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data
19 January 2026
